Activation of insulin‐like growth factor‐1 receptor confers acquired resistance to osimertinib in non‐small cell lung cancer with EGFR T790M mutation

BACKGROUND: Osimertinib (AZD9291) is a third‐generation EGFR‐tyrosine kinase inhibitor (TKI) that selectively inhibits the activating EGFR mutation and T790M mutation, and is currently used globally to treat EGFR‐mutant non‐small cell lung cancer (NSCLC). However, acquired resistance to osimertinib...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Thorac Cancer
Main Authors: Hayakawa, Daisuke, Takahashi, Fumiyuki, Mitsuishi, Yoichiro, Tajima, Ken, Hidayat, Moulid, Winardi, Wira, Ihara, Hiroaki, Kanamori, Koichiro, Matsumoto, Naohisa, Asao, Tetsuhiko, Ko, Ryo, Shukuya, Takehito, Takamochi, Kazuya, Hayashi, Takuo, Suehara, Yoshiyuki, Takeda Nakamura, Ikuko, Ueno, Toshihide, Kohsaka, Shinji, Mano, Hiroyuki, Takahashi, Kazuhisa
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley & Sons Australia, Ltd 2019
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6938756/
https://ncbi.nlm.nih.gov/pubmed/31758670
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1759-7714.13255
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados